A recent policy change by Merck to offer greater discounts for its cholesterol-lowering drug Zocor has employers, pharmacy benefit managers and insurers faced with making a tough decision: Should they follow what has been general tradition to this point and offer generic versions (simvastatin) at the lowest discounts to their customers, or should they instead buck conventional thinking and offer brand-name Zocor at the lowest costs? Industry experts say employers should pay astute attention to the pricing methodologies of Zocor and simvastatin and ensure they know through their PBM what their net gain is, if any.
Most Popular
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
13 Job Interview Mistakes To Avoid
Public Speaking: 7 Secrets Of Great Public Speakers
3 Questions No Job Seeker Ever Wants To Be Asked?
The predicament started June 23 when Merck’s primary U.S. patent on Zocor expired, thereby granting Ranbaxy Laboratories and Teva Pharmaceutical Industries approval from the Food and Drug Administration to manufacture and sell generic simvastatin for a period of 180 days of exclusivity. When the exclusivity period expires in December, all generic firms and mail-order …
Read the full article with a Free Trial at MyWire.